RADA-16 Reduces Postoperative Epistaxis After Inferior Turbinate Submucosal Resection.

Area of Science:

• Biomaterials Science
• Otorhinolaryngology
• Surgical Innovation

Background:

• RADA-16 is a self-assembling peptide forming a hydrogel.
• It shows potential for wound healing and hemostasis.
• Inferior turbinate submucosal resection (ITR) can lead to postoperative bleeding (epistaxis).

Purpose of the Study:

• To evaluate the efficacy of RADA-16 in reducing postoperative bleeding rates.
• To assess the utility of RADA-16 following ITR surgery.
• To compare healthcare costs associated with RADA-16 use.

Main Methods:

• Retrospective study analyzing electronic health records.
• Included 985 patients undergoing ITR surgery.
• Compared epistaxis rates and costs between RADA-16 and non-RADA-16 cohorts using univariate and multivariate analyses.

Main Results:

• 0.35% of patients receiving RADA-16 experienced bleeding versus 2.17% in the non-RADA-16 group.
• RADA-16 use was associated with a significantly lower risk of postoperative hemorrhage (OR 0.17, p=0.026).
• No significant difference in additional nasal surgery or bleeding disorders; bleeding cost per patient was lower in the RADA-16 group ($379.74 vs $436.21).

Conclusions:

• RADA-16 demonstrates effectiveness in improving hemostasis.
• Patients treated with RADA-16 experienced significantly less epistaxis after ITR surgery.
• RADA-16 is a promising adjunct for minimizing postoperative bleeding in ITR procedures.